fosaprepitant dimeglumine

DRUG10 trials

Conditions

Breakthrough Nausea and VomitingBreast CancerChemotherapy-Induced Nausea and Vomiting (CINV)Chemotherapy-induced Nausea and VomitingGastrointestinal CancerGenital Neoplasms, FemaleLocally Advanced SarcomaMalignant Neoplasm

Phase 1

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

TerminatedNCT01031953

OHSU Knight Cancer InstituteBreakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2008-08-31End: 2013-02-28Updated: 2017-05-09

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

TerminatedNCT01649258

University of Southern CaliforniaBreast Cancer, Nausea, Vomiting

Start: 2012-09-04End: 2017-09-30Updated: 2017-11-17

Phase 2

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

TerminatedNCT00895245

University of WashingtonNausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx +8

Start: 2009-02-28End: 2011-02-28Updated: 2017-05-18

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

TerminatedNCT01405924

Merck Sharp & Dohme LLCNausea, Vomiting

Start: 2011-10-25End: 2013-12-06Updated: 2018-08-27

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

TerminatedNCT02732015

M.D. Anderson Cancer CenterLocally Advanced Sarcoma

Start: 2016-10-12End: 2020-07-10Updated: 2021-08-09

Phase 3

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

CompletedNCT01074697

Odense University HospitalGenital Neoplasms, Female, Nausea, Vomiting

Start: 2010-04-30End: 2015-04-30Updated: 2015-04-24

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

CompletedNCT01594749

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2012-09-24End: 2014-11-03Updated: 2018-09-04

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

CompletedNCT03578081

Alliance for Clinical Trials in OncologyMalignant Neoplasm

Start: 2018-11-20End: 2023-05-01Updated: 2025-04-06

Phase 4

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

CompletedNCT04054193

Merck Sharp & Dohme LLCChemotherapy-induced Nausea and Vomiting

Start: 2019-09-09End: 2021-02-11Updated: 2025-01-16

Unknown Phase

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

CompletedNCT01504711

Philip PhilipGastrointestinal Cancer, Nausea Post Chemotherapy

Start: 2012-06-30End: 2020-09-03Updated: 2021-04-08

The Oncologist2023-06-071 citations

Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).

Journal of Clinical Oncology2022-06-011 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

BMC Cancer2020-09-259 citations

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.

2018-05-288 citations

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

Cancer Research2018-02-152 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.

Journal of Clinical Oncology2017-05-20

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.

2016-03-0427 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

2015-10-0855 citations

A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Journal of Clinical Oncology2015-05-203 citations

Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

Journal of Clinical Oncology2014-05-20